Siegel R, Miller K. Jemal A. Cancer statistics. 2018;2018(68):7–30.
Tan H, Sood A, Rahimi H, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;20:890–903.
Aggarwal R, Huang J, Alumkal J, Zhang L, Feng F, Thomas G, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492–503.
Beltran H, Tagawa S, Park K, MacDonald T, Milowsky M, Mosquera J, et al. Nanus DJJocoojotASoCO: Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012;30:e386–9.
Wang H, Yao Y, Li B, Tang Y, Chang J, Zhang J. Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. 2014;32:3383–90.
Mohler J, Antonarakis E, Armstrong A, D'Amico A, Davis B, Dorff T, et al. Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:479–505.
Humphrey P, Moch H, Cubilla A, Ulbright T, Reuter VJE. The 2016 WHO Classification of Tumours of the Urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70:106–19.
Epstein J, Amin M, Beltran H, Lotan T, Mosquera J, Reuter V, Robinson B, Troncoso P, Rubin M. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38:756–67.
Klimstra D, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015:92–103.
Ather M, Abbas F, Faruqui N, Israr M, Pervez S. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol. 2008;8:21.
Kaarijärvi R, Kaljunen H, Ketola KJC: Molecular and functional links between neurodevelopmental processes and treatment-induced neuroendocrine plasticity in prostate cancer progression. 2021, 13.
Akamatsu S, Inoue T, Ogawa O, Gleave M. Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int J Urol. 2018;25:345–51.
Lotan T, Tomlins S, Bismar T, Van der Kwast T, Grignon D, Egevad L, et al. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. I. Molecular Biomarkers in Prostate Cancer. Am J Surg Pathol. 2020;44:e15–29.
Tagawa S. Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle. J Clin Oncol. 2014;32:3360–4.
Niu Y, Guo C, Wen S, Tian J, Luo J, Wang K, et al. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis. Cancer Lett. 2018;439:47–55.
Beltran H, Prandi D, Mosquera J, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298–305.
Aparicio A, Shen L, Tapia E, Lu J, Chen H, Zhang J, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016;22:1520–30.
Wang K, Ruan H, Xu T, Liu L, Liu D, Yang H, et al. Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer. Onco Targets Ther. 2018;11:3167–78.
Loeb S, Feng Z, Ross A, Trock B, Humphreys E, Walsh P. Can we stop prostate specific antigen testing 10 years after radical prostatectomy? J Urol. 2011;186:500–5.
Liesenfeld L, Kron M, Gschwend J, Herkommer K. Prognostic factors for biochemical recurrence more than 10 years after radical prostatectomy. J Urol. 2017;197:143–8.
Drent M, Cobben N, Henderson R, Wouters E, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J. 1996;9:1736–42.
Kim J, Dang C. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927–30.
Zhang X, Guo M, Fan J, Lv Z, Huang Q, Han J, et al. Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Cancer Biomark. 2016;16:415–23.
Mori K, Kimura S, Parizi M, Enikeev D, Glybochko P, Seebacher V, et al. Prognostic value of lactate dehydrogenase in metastatic prostate cancer: a systematic review and meta-analysis. Clin Genitourin Cancer. 2019;17:409–18.
Conteduca V, Scarpi E, Salvi S, Casadio V, Lolli C, Gurioli G, et al. Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. Sci Rep. 2018;8:15442.
Vitkin N, Nersesian S, Siemens D, Koti M. The tumor immune contexture of prostate cancer. Front Immunol. 2019;10:603.
Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–8.
Teo M, Seier K, Ostrovnaya I, Regazzi A, Kania B, Moran M, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36:1685–94.
Xu Y, Song G, Xie S, Jiang W, Chen X, Chu M, et al. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer; 2021.
Petitprez F, Fossati N, Vano Y, Freschi M, Becht E, Lucianò R, et al. PD-L1 expression and CD8 T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer. Eur Urol Focus. 2019;5:192–6.
Vicier C, Ravi P, Kwak L, Werner L, Huang Y, Evan C, et al. Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer. Prostate. 2021;81:50–7.
Ruiz de Porras V, Pardo J, Notario L, Etxaniz O, Font A. Immune checkpoint inhibitors: a promising treatment option for metastatic castration-resistant prostate cancer? 2021, 22.